--On pace for largest percent decrease since June 25, 2019, when it fell 16.25% --Currently down four consecutive days; down 14.17% over this period ...

AbbVie shares, which hit a 52-week high in late October after the drugmaker posted quarterly earnings that topped Wall Street's expectations and raised its dividend by nearly 6%, were recently down ...

This will be a strong overall net benefit, however, given the company's history on membership fee increases ... At the end of ...

AbbVie added emraclidine via the approximately $8.7 billion acquisition of Cerevel Therapeutics. The program also includes an ...